CellPly announces acceptance of one abstract at the CICON23 conference

BOLOGNA, Italy, September 18, 2023 – CellPly, the pioneer in multiparametric single-cell analysis and automated potency testing for cell therapy, today announced that it will present data in a poster presentation at the Seventh International Cancer Immunotherapy Conference: Translating Science into Survival, being held in Milan, Italy, on Sep. 20-23, 2023.

The data reported in this abstract, generated within a scientific collaboration with the team of Dr. Richard Harbottle at the DKFZ institute, Heidelberg, Germany, show the characterization of TCR-T cells engineered from Dr. Harbottle’s team through the VivaCyte® technology for the analysis of cell function at the single-cell resolution developed at Cellply. Thanks to a novel single-cell serial killing assay, researchers were able to demonstrate that T cells engineered with a non-viral DNA nanovector acquire the capacity to exert their cytotoxic function multiple times before their exhaustion, leading to an increase in T cell potency.

Details of the poster presentation are as follows:

Title: Single-cell cytotoxicity analysis identifies serial killer transgenic TCR-T cells manufactured using non-viral S/MAR DNA nanovectors
Abstract number: P528
Session: POSTER SESSION A – EVEN NUMBERS Thursday, Sept. 21
Link to abstract

About Cellply
CellPly is a life-science company developing analytical tools aiming at unraveling the complexity of the immune system and enabling rapid and effective development of next-generation immunotherapies and cell-based therapies. Our unique solution combines a proprietary microfluidic technology to capture functional and phenotypic information from thousands of single cells, with the highly automated VivaCyte® analytical instrument, integrating robotic solutions and AI for image analysis. Our goal is to make in-depth analysis applicable across the therapy development cycle, from discovery to process development and quality control.


Follow us
LinkedIn: https://www.linkedin.com/company/cellply
Twitter: https://twitter.com/cellply

Comments are closed.